Canada-UK: Biomanufacturing of Biologics

Fund details

Your joint Canadian and UK project can focus on one or more of the following:

Enabling technologies for biologics and advanced therapeutics

• discovery, design and high throughput screening platforms, which may include the application of artificial intelligence
• manufacturing systems and methods, for example: centralised, distributed or point‑of‑care; microfluidics‑based devices, new and innovative systems for Good Manufacturing Practice production, fill and finish, automation security
• manufacturing process intensification enablers, for example hyper productive strains, novel expression systems, continuous production processes, perfusion technologies
• novel analytical characterization, potency assays and real‑time release technologies, biosensors
• other relevant enabling technologies

Delivery systems for proteins and nucleic acids

• viral and non‑viral (for example, lipid nanoparticles) platforms, including their components and payloads

Novel biological products

• vaccines, for example: prophylactic, therapeutic and various platforms
• therapeutic proteins, for example: antibodies, and related production process‑intensification enablers
• advanced therapy medicinal products, for example: mRNA, siRNA, gene therapies, cell therapies engineered tissues
• other biological-based therapies, for example: bacteriophage, engineered probiotics

Eligibility

Canadian funding applicants are required to register and submit an expression of interest (EoI) before being eligible to apply for this competition.

The registration deadline for Canadian micro, small or medium-sized enterprises (SMEs) is 2 July 2024.

Projects must:

• have a grant funding request of no more than £600,000 allocated to UK organisations
• have a total grant funding request for Canadian partners of no more than CA$1 million